Drugs / Osivelotor
Osivelotor
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT06507904 | Sep 2026 → Feb 2027 expected | — | Pfizer | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06340347 | Apr → Sep 2024 | liver disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06190561 | Jan → May 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05878704 | Jun 2023 → Jul 2024 | impaired renal function disease | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05718687 | Dec 2022 → Aug 2023 | sickle cell disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04983264 | May 2021 → Dec 2022 | sickle cell disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05036512 | Dec 2020 → Nov 2022 | sickle cell disease | Pfizer | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05632354 | Jan 2023 → Feb 2025 | sickle cell disease | Pfizer | Terminated | No outcome recorded |
| Phase 2/3 | NCT05431088 | Sep 2022 → Dec 2030 expected | sickle cell disease | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Osivelotor | “Osivelotor (GBT021601) is an orally bioavailable, small molecule hemoglobin polymerization inhibitor in clinical development for the treatment of sickle cell disease (SCD).” PMID 42183775 ↗ Jun 2026 |
| Known as | GBT021601 | “Osivelotor (GBT021601) is an orally bioavailable, small molecule hemoglobin polymerization inhibitor in clinical development for the treatment of sickle cell disease (SCD).” PMID 42183775 ↗ Jun 2026 |
| Known as | GBT601 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314424 ↗ |
| Known as | PF-07940367 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06190561 ↗ |
| Action | Inhibit | “hemoglobin S (HbS) polymerization inhibitor” NCT04983264 ↗ |
| Modality | Small molecule | “a novel, small molecule, sickle hemoglobin (HbS) polymerization inhibitor.” PMID 40832524 ↗ Jul 2025 |
| Route | Oral | “Administered orally with water as a single dose in the morning.” NCT05036512 ↗ |